Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance.
Yue Y, Cao Y, Mao X, Wang F, Fan P, Qian L, Guo S, Li F, Guo Y, Chen T, Lin Y, Dong W, Liu Y, Huang Y, Gu W.
Yue Y, et al. Among authors: guo s, guo y.
Front Oncol. 2022 Aug 5;12:894279. doi: 10.3389/fonc.2022.894279. eCollection 2022.
Front Oncol. 2022.
PMID: 35992875
Free PMC article.